Free tool
FAERS Monitor: Ampyra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022250 or its brand name (Ampyra, Dalfampridine). Reports on generic versions are filed under their own applications.
Reports
71,576
Serious
20,310
28% of reports
Hospitalization
10,210
Death reported
1,771
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gait disturbance10,994
- drug ineffective8,325
- fall7,361
- fatigue5,556
- balance disorder4,909
- multiple sclerosis relapse4,788
- therapy cessation4,511
- dizziness4,000
- urinary tract infection3,747
- condition aggravated3,514
- asthenia3,471
- insomnia3,311
- headache3,274
- multiple sclerosis3,136
- mobility decreased3,008
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 686 |
| 2011 | 837 |
| 2012 | 1,050 |
| 2013 | 1,618 |
| 2014 | 6,349 |
| 2015 | 7,532 |
| 2016 | 12,012 |
| 2017 | 10,164 |
| 2018 | 10,789 |
| 2019 | 7,166 |
| 2020 | 3,152 |
| 2021 | 2,695 |
| 2022 | 2,758 |
| 2023 | 2,247 |
| 2024 | 992 |
| 2025 | 748 |
| 2026 | 772 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,982,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy cessationSignal | 4,511 | 28.2 | 27.4 | 108,249 |
| multiple sclerosis relapseSignal | 4,788 | 22.0 | 21.4 | 89,524 |
| multiple sclerosisSignal | 3,136 | 20.6 | 19.8 | 54,620 |
| gait disturbanceSignal | 10,994 | 17.8 | 17.5 | 166,286 |
| balance disorderSignal | 4,909 | 17.6 | 17.1 | 72,931 |
| mobility decreasedSignal | 3,008 | 12.8 | 12.3 | 31,440 |
| fallSignal | 7,361 | 6.6 | 6.5 | 34,915 |
| urinary tract infectionSignal | 3,747 | 6.6 | 6.4 | 17,469 |
| insomniaSignal | 3,311 | 3.7 | 3.6 | 6,481 |
| condition aggravatedSignal | 3,514 | 3.4 | 3.3 | 6,047 |
| astheniaSignal | 3,471 | 2.7 | 2.6 | 3,833 |
| dizzinessSignal | 4,000 | 2.4 | 2.3 | 3,209 |
| fatigueSignal | 5,556 | 2.1 | 2.1 | 3,321 |
| drug ineffective | 8,325 | 1.9 | 1.8 | 3,519 |
| headache | 3,274 | 1.5 | 1.5 | 630 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.